Poseida Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Poseida Therapeutics

12/05/2022 23:22

* Poseida Therapeutics Inc  PSTX.OQ  reported a quarterly
adjusted
loss of 93 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 66 cents per share.
    * Revenue was $1.44 million​;  analysts expected $625.00
thousand. 
    * Poseida Therapeutics Inc's reported EPS for the quarter
was a
loss of 93 cents​.
    * The mean earnings estimate of analysts had fallen by
about 3.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Poseida Therapeutics Inc shares had fallen by 58.3% this
quarter and lost 72.5% so far this year.
    * The company reported a quarterly loss of $58.06 million.
    * Wall Street's median 12-month price target for Poseida
Therapeutics Inc is $21.50 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated May 12 at 10:21 p.m.  ​All
figures in US dollars unless otherwise stated